Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.

A retrospective study revealed differences in metastasis patterns and treatment utilization by ethnicity among patients with breast cancer and brain metastasis.

Patients mainly experience bone metastasis, which develops when the cancer cells migrate to the bone from another affected ...

Chemotherapy, hormonal therapy, or radiation therapy, have been the primary modes of treatment for patients with bone metastases, but substantial morbidity from progressive skeletal involvement ...

Raman is also a member of the Johns Hopkins Kimmel Cancer Center. “We first had to determine whether DDX3 was expressed in ...

From there, metastatic cells travel even further back in time — back to a point before they’re locked into becoming intestinal cells and can instead become skin or bone or nerve cells. “The signature ...

From there, metastatic cells travel even further back in time—back to a point before they're locked into becoming intestinal cells and can instead become skin or bone or nerve cells.

Their findings hold promise for advancing the development of preclinical tools to predict breast cancer bone metastasis. Breast cancer is a significant global public health challenge, with 2.3 million ...

In a new study led by Johns Hopkins Medicine, the drug RK-33 has demonstrated promise in treating breast cancer that has spread to the bone (breast cancer bone metastasis).RK-33 was previously ...

The new occurrences of cancer are called metastases. A phenotypic study to examine the distinct morphologies of ER+ and ER− breast cancer bone metastases focusing on the mechanism associated ...